EN 
FR DISEASES SIGNATURES USING METABOLOMICS ANALYSIS
Through the identification of multi-omics disease signatures, we accelerate the innovation cycle in prevention, diagnostics, treatment monitoring and AI drug discovery.
Linearis Labs | About our work
Linearis Labs is expanding omics testing and discovery capabilities. Linearis Labs operates from our 9000 sq ft (800m2) laboratory.
Linearis offers metabolomics profiling services. Services include both targeted and untargeted LC-MS measurements. High throughput procedures are also available to process thousands of samples. The analyses are carried out in a clinical grade environment.
We work with leaders in both AI and metabolomics to generate quantitative and actionable AI-friendly data as part of their AI pipelines. Some recent work involves omics signatures for COVID-19 and cancer. Linearis Labs couples high throughput technology and mass spectrometry to provide metabolomics analysis of blood plasma.
Linearis Labs couples high throughput technology and mass spectrometry to provide metabolomics analysis of minimal amounts of biological fluids for diseases in cancer, diabetes, cardiology, neurology and antimicrobial resistance which have significant metabolomics components.
Using the AI pipeline GigaView, disease signatures are discovered and can provide actionable insights for several types of metabolomics diseases, improve effectiveness of therapeutic interventions, and prevent the emergence of resistance and side effects of treatments.
Linearis Labs offers metabolomics profiling services for biobanks using both a targeted 1780 metabolomic assay and untargeted LC-MS/MS analyses.
Metabolomic Analysis
As metabolomics is closer to the phenotype, it provides a great advantage for biobanks to acquire metabolomics data.
Moreover, there is an expectation that multi-omics analyses will be required for better interpretation of the diseases under investigation.
The data is made available in an AI-friendly format for machine learning-based analysis. Linearis Labs can also perform data analysis with state-of-the-art machine learning algorithms.
VISION
Accelerate innovation in AI for the benefit of health companies focused on disease prevention, monitoring, and drug discovery.
MISSION
Linearis is building a unified AI platform for metabolomics that reveals disease signatures to accelerates drug development, screening, and monitoring across metabolic diseases spanning oncology, cardiology, neurology, diabetes, and antimicrobial resistance.
VALUES
Make our work accessible to all
Build trust in the quality of our data
Strive for excellence in everything we do
Create sustainable, positive impacts through our technologies
Innovate and provide value for our partners and collaborators
Maintain integrity in our work ethics
Have passion for improving people’s health